Introduction {#Sec1}
============

Patients who develop neuroendocrine and other tumour entities overexpressing peptide receptors can be treated with peptide receptor radionuclide therapy (PRRT) leading to longer survival and improved quality of life \[[@CR1]\]. This molecular targeted radiation therapy involves the systemic administration of a radiolabelled peptide designed to target the overexpressed receptors on tumour cells with high affinity and specificity \[[@CR1]\]. In the past 15 years, PRRT with the radiolabelled somatostatin receptor agonists ^90^Y-DOTA-D-Phe-Tyr3-octreotide (^90^Y-DOTATOC), ^177^Lu-DOTA-D-Phe-Tyr3-octreotate (^177^Lu-DOTATATE) and ^177^Lu-DOTA-D-Phe-Tyr3-octreotide (^177^Lu-DOTATOC) have been successfully used to target metastatic and inoperable neuroendocrine tumours (NET) expressing somatostatin receptor subtype 2 \[[@CR1]--[@CR3]\]. PRRT has also been used to treat meningioma \[[@CR4]--[@CR7]\] and thyroid cancer \[[@CR8]--[@CR10]\].

The haematological toxicity of this treatment is an issue, since it has been observed particularly after the administration of ^90^Y-labelled DOTA compounds \[[@CR11]\], whereas treatment with ^177^Lu-labelled compounds delivers lower absorbed doses to the bone marrow \[[@CR12]\]. In agreement with this, patients receiving ^177^Lu-DOTATATE/DOTATOC did not show haematological toxicity with the exception of one with grade 3 leukopenia and thrombocytopenia \[[@CR13]\]. In any case, systemic administration of therapeutic radionuclide activities will lead to DNA damage because of the protracted whole-body irradiation.

PRRT also provides the opportunity to study the effects of prolonged systemic β- and γ-irradiation after administration of ^177^Lu in vivo. In this setting, all organs including the blood are irradiated by β-particles emitted from circulating ^177^Lu and from penetrating γ-radiation originating from activity dispersed throughout the body. The absorbed dose and dose rate to the blood after systemic administration of ^177^Lu-labelled compounds is assessed by defining the time--activity curves in the blood and the whole body, integrating the corresponding time--activity curves and calculating the absorbed dose \[[@CR14]\].

Furthermore, radiation exposure can be correlated with biological effects, including DNA damage that is assessed biodosimetrically in terms of chromosome aberrations or DNA double strand breaks (DSBs). DSBs are critical cellular lesions that can result from genotoxins such as ionizing radiation or chemical compounds \[[@CR15]--[@CR17]\]. Their formation in nuclear chromatin results in rapid phosphorylation of the histone H2 variant H2AX, called γ-H2AX \[[@CR15], [@CR18], [@CR19]\]. DSBs also recruit the damage sensor 53BP1 to the chromatin surrounding the DSBs \[[@CR20]--[@CR24]\], which leads to 53BP1 and γ-H2AX colocalization in the chromatin surrounding a DSB \[[@CR20], [@CR22], [@CR25]--[@CR27]\]. Therefore, radiation-induced DSBs can be addressed by microscopically visible DNA damage protein foci that display both γ-H2AX and 53BP1 immunofluorescence \[[@CR27]\]. With progression of DSB repair, γ-H2AX and 53BP1 foci disappear \[[@CR28]\]. The immunofluorescence staining for colocalizing γ-H2AX/ 53BP1 foci and their quantification as DSBs has been termed the DNA damage focus assay \[[@CR26], [@CR27]\].

At present, there are only two studies that have quantified radiation-induced DNA damage focus formation after treatment of differentiated thyroid cancer (DTC) with the isotope ^131^I, either using radiation-induced colocalizing γ-H2AX and 53BP1 foci \[[@CR29]\] or γ-H2AX foci only \[[@CR30]\]. A more recent study has addressed γ-H2AX foci formation after ^177^Lu therapy of NET \[[@CR31]\]. In these studies elevated levels of radiation-induced DNA damage foci were observed after treatment, but a dose--response relationship could not be established.

The aims of the present study were therefore, (a) to establish a methodology for describing absorbed doses to the blood in patients after PRRT similar to the formalism developed for radioiodine therapy of thyroid cancer \[[@CR32]\], (b) to describe the temporal and dose-dependent behaviour of the DNA damage focus assay in radiation treatment-naive patients after their first PRRT with ^177^Lu, (c) to compare the in vivo dose response in the first hours after therapy with an in vitro calibration curve established recently in our laboratory \[[@CR27]\], and (d) to describe and quantify the decay of foci at later time-points after administration of the radiopharmaceutical as a potential measure of the repair of radiation-induced double stranded DNA damage in vivo.

Materials and methods {#Sec2}
=====================

Research design and subjects {#Sec3}
----------------------------

Patients referred to our centre for initial treatment with ^177^Lu-labelled DOTATATE/DOTATOC were included in this study. The treatment was done on a compassionate use basis in patients with an advanced stage of their disease or who were without any other therapeutic options. Haematological disease was an exclusion criterion. During the week prior to treatment with radiolabelled peptides patients were requested not to receive ionizing radiation for diagnosis and/or treatment.

Before PRRT, patients were hospitalized in our ward to check their medical condition. On the treatment day, a mixture of [l]{.smallcaps}-arginine and [l]{.smallcaps}-lysine was given immediately before PRRT over 3.5 to 4 h to reduce the dose to the kidneys \[[@CR1]\]. The ^177^Lu-labelled DOTATATE/TOC activity was then delivered using a perfusion system over a period of 20 min. The end of the administration process was chosen as the starting point of the study. After the start of treatment the patients stayed in our ward for 2 days.

Blood sampling and activity determination in blood samples {#Sec4}
----------------------------------------------------------

Blood samples were drawn in all patients prior to administration and nominally at 1, 2, 3, 4, 24 and 48 h after administration using Li-heparin blood collecting tubes (S-Monovette, Sarstedt, Germany). For exact quantification of the blood activity concentration, an aliquot of 0.1 mL of each heparinized blood sample was measured in a well counter (Canberra, Germany) or in a high-purity germanium detector (Canberra, Germany). The counting efficiencies of the detectors were determined by repeated measurements of a NIST-traceable standard. The measured values were decay-corrected to the time of blood sampling.

Blood sample preparation for the DNA damage focus assay {#Sec5}
-------------------------------------------------------

Separation and fixation of white blood cells and counting of the foci followed the protocol described by Eberlein et al. \[[@CR27]\] the foci being stained according to the procedure described by Lassmann et al. \[[@CR29]\] and Lamkowski et al. \[[@CR26]\]. The average numbers of radiation-induced damage foci (RIF) per cell were obtained by subtracting the background number of foci for each counted sample. A detailed description of this method is provided in the [Supplementary material](#MOESM1){ref-type="media"}.

Measurement of the whole-body retention {#Sec6}
---------------------------------------

Whole-body activity retention was determined in all patients by combining external dose rate measurements and whole-body gamma camera scans. For the first measurement, the patients were asked not to micturate or defaecate after administration of the radiopharmaceutical. Prior to subsequent measurements they were asked to micturate. The dose-rate measurements were performed using a ceiling-mounted shielded survey meter (automess--Automation und Messtechnik, Germany) at a fixed distance of 2.5 m above the patient's bed. The patient measurements were carried out immediately after administration and at least two times per day thereafter. The data were normalized to the first initial measurement. In addition, whole-body scans with a gamma camera (Symbia T2; Siemens Healthcare, Germany) were performed 1 h and 24 h after administration (medium energy collimator, energy window 208 keV ±10 %). In selected patients, an additional scan was performed 4 h after treatment. The gamma camera whole-body retention was calculated by normalizing the geometric mean of subsequent background-corrected anterior and posterior counts to the initial measurement. Both datasets were combined to obtain the whole-body retention curve for each patient.

Calculation of the time-integrated activity coefficients and the absorbed doses {#Sec7}
-------------------------------------------------------------------------------

A biexponential fit function was adequate to determine the function describing the activity as a function of time for the whole body and blood. The time-integrated activity coefficients for the whole body and activity concentration in blood (τ~total\ body~(*t*) and τ~ml\ of\ blood~(*t*)) were calculated by integrating the respective time--activity functions over time. Note the unit of τ~total\ body~ is hours and the unit of τ~ml\ of\ blood~ is hours per millilitre because we considered only a small blood volume (0.1 ml) for our measurements in the well counter. The absorbed doses were calculated using a procedure analogous to the EANM standard operational procedure for dosimetry in the treatment of DTC \[[@CR32]\] using the following equation:$$\documentclass[12pt]{minimal}
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where *A*~0~ is the administered activity and *wt* is the patient's weight in kilograms. The method is described in more detail in the [Supplementary material](#MOESM1){ref-type="media"}.

Modelling the time-dependency of focus induction and disappearance {#Sec8}
------------------------------------------------------------------

Most in vitro and in vivo studies of ionizing radiation-induced DSB formation have indicated a linear relationship between the number of microscopically visible RIF and the absorbed dose \[[@CR15], [@CR18], [@CR27], [@CR33]\], the dose--length product in CT examinations \[[@CR34], [@CR35]\] or the total body dose in radiotherapy \[[@CR36]\]. For our set-up and staining procedure we also observed a linear dose--response relationship between the absorbed dose to the blood and the number of RIF per cell in an in vitro experiment \[[@CR27]\].

As has been pointed out by Dale and Fowler \[[@CR37]\], sublethal DNA damage repairs monoexponentially, assuming that the rate of repair at any instant is directly proportional to the number of unrepaired lesions remaining (first-order process). However, the same authors found that monoexponential repair could not completely explain the observations made in several clinical studies \[[@CR37]\]. The easiest way to account for this would be to introduce a multiexponential model with different repair rates. Another model introduced by Fowler \[[@CR38]\] and by Dale et al. \[[@CR39]\] assumes that the rate of repair of damaged lesions is proportional to the square of their number (second-order process); a finding, however, that has not been confirmed yet for the DNA damage focus assay. Studies of the DNA damage focus assay by Horn et al. \[[@CR40]\] and Mariotti et al. \[[@CR41]\] have revealed that the number of RIF per cell decreases over time with the onset of DNA repair, following a biexponential model \[[@CR40], [@CR41]\]. Hence, we decided to describe the decrease in the number of RIF per cell over time with a biexponential model. Therefore, the time dependency of the number of RIF per cell as a function of the time-dependent absorbed dose and the disappearance of foci can be described in the low absorbed dose range by a linear dose-dependent increase using the input of our in vitro calibration curve and biexponential decay representing DNA repair:$$\documentclass[12pt]{minimal}
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where:*N*(*t*) is the number of foci at time *t*.*m* is an adjustable parameter to account for the variability in patient dosimetry with respect to the in vitro calibration established by Eberlein et al. \[[@CR27]\].*a* and *b* are constants describing the in vitro calibration curve \[[@CR27]\] representing the number of RIF per cell as a function of the mean time-dependent absorbed dose $\documentclass[12pt]{minimal}
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                \begin{document}$$ \overline{D} $$\end{document}$~blood~(*t*) is the mean absorbed dose to the blood (Eq. [1](#Equ1){ref-type=""}).*λ* and *υ* are patient-specific adjustable parameters describing the decay rate of foci.*k* is an adjustable parameter describing the fraction of damage assigned to different repair rates. Since we performed only two measurements at time-points \>12 h, for this study, we set *k* = 1.

Statistics {#Sec9}
----------

Origin (version 9.1G + 2015G, Origin Lab Corporation) was used for data analysis and statistical evaluation. The normal distribution of the datasets was tested using the Shapiro-Wilk test. RIF per cell value data sets at different time-points were compared using the paired *t* test. Differences were considered significant for *p* \< 0.05.

Results {#Sec10}
=======

Patients {#Sec11}
--------

Of 18 patients enrolled in the study, 16 were included (mean age 61.2 ± 10.5 years, Table [1](#Tab1){ref-type="table"}). The patient demographics are given in Table [1](#Tab1){ref-type="table"}. Ten of the patients presented with NET. Other diseases included adrenocortical cancer, meningioma and papillary thyroid carcinoma. All patients except one presented with metastases. Thirteen patients were referred to our centre because of progressive disease. The pretreatment of these patients included surgery, chemotherapy, radiotherapy, sandostatin, mitotane and everolimus. All pretreatment was discontinued \>1.5 months before PRRT.Table 1Patient demographic dataPatient IDAge (years)Weight (kg)Activity (GBq)CompoundTumourLocal recurrenceLocation of metastasesIndicationPretreatmentGrade/Ki67 (%)Lu165.8967.03DOTATOCNET, jejunumNoLymph nodesPDSurgeryG1/2Lu256.5946.41DOTATOCNET, pancreaticNoLiver, bonePDCTx, everolimusG2Lu372.8927.94DOTATOCPapillary thyroid cancerNoLymph nodes, lungPDSurgery, RIT, CTx--Lu467.9826.60DOTATOCUnknown primaryNoBone, liverPDSandostatinG2Lu554.31006.90DOTATOCAdrenocortical cancerYesLymph nodes, peritonealPDSurgery, CTx--Lu667.1947.60DOTATOCNET, lungNoLymph nodes, pleura, bonePDCTx\>90 %Lu756.4417.00DOTATOCAdrenocortical cancerYesLung, peritonealPDSurgery, CTx, mitotane--Lu830.6957.30DOTATOCNET, lungNoBone, liver, lymph nodesPDCTx, RTx--Lu1068.5827.05DOTATOCNET, ileumNoLiver, lung, lymph nodesPDSandostatin--Lu1167.2707.13DOTATOCNET, ileumNoLiver, lymph nodesPDSurgery--Lu1261.5707.70DOTATATEMeningiomaYes--PDRTx--Lu1361.4647.70DOTATATENET, pancreaticNoLymph nodesPT--G2Lu1448.8607.54DOTATATENET, lungNoLymph nodesPT--100 %Lu1667.5797.01DOTATATEUnknown primaryNoLiverPT--xLu1761.3756.97DOTATATENET, ileumNoLymph nodes, liver, peritonealPDSurgery, sandostatinG2Lu1872.2676.99DOTATATENET, gastricNoLiverPDSandostatinG2*PD* progressive disease, *PT* primary treatment, *NET* neuroendocrine tumour, *CTx* chemotherapy, *RIT* radioiodine therapy, *RTx* radiotherapy

For PRRT the patients received ^177^Lu-labelled DOTATATE (patients 1 -- 11) or DOTATOC (patients 12 -- 18) intravenously (mean activity 7.2 ± 0.4 GBq) via a perfusion system over 20 min. Patients were then admitted to our ward and discharged 2 days later. All blood samples and measurements were taken during this time period. All patients responded well to the treatment or showed disease stabilization at follow-up and showed no therapy-related or study-related adverse effects.

DNA damage foci {#Sec12}
---------------

Peripheral blood lymphocytes were immunofluorescently stained for γ-H2AX/53BP1 DNA damage foci and manually counted for colocalizing DSB-marking foci. The average numbers of RIF per cell were calculated subtracting the number of background foci for the different patient samples (Fig. [1](#Fig1){ref-type="fig"}) as a function of time after administration of the radiopharmaceutical. The average number of RIF per cell increased in the first hours after therapy, decreasing at later time-points (Fig. [1](#Fig1){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). The actual time-points differed slightly because of variations in management of individual patients. The mean numbers of RIF per cell were 0.55 at 4 h, 0.42 at 24 h, and 0.43 at 48 h after administration of ^177^Lu. Distribution analysis of the numbers of RIF per cell identified the 48-h value in patient Lu10 as an outlier that was excluded from further analysis. All three datasets were distributed according to a Gaussian distribution (Shapiro-Wilk test). Applying the paired *t* test to all time-points revealed that there were statistically significant differences among the numbers of RIF per cell at these different time-points (*p* \< 0.008) confirming the observation that the number of RIF per cell decreased 5 h after administration of the radiopharmaceutical.Fig. 1Average RIF per cell as a function of time after administration of ^177^Lu: **a** all data, time-points 0 -- 48 h; **b** detailed view of time-points 0 -- 5 hTable 2Number of RIF per cell and absorbed doses at different time-pointsPatient IDBackground foci valuesNominal time-points4 h24 h48 hAbsorbed dose (mGy)No. of RIF per cellAbsorbed dose (mGy)No. of RIF per cellAbsorbed dose (mGy)Gamma contribution (%)No. of RIF per cellLu10.0327.10.5644.40.2753.6190.20Lu20.0123.70.4250.70.3168.0290.34Lu30.0642.00.4963.60.3976.8160.29Lu40.2016.40.7040.50.5957.4330.36Lu50.0245.10.3885.20.23110.4110.11Lu60.0429.10.7455.20.2575.5180.23Lu70.0358.90.6586.40.3795.570.38Lu80.168.40.4434.10.5157.5340.19Lu100.0536.50.9265.70.5785.0180.82^a^Lu110.3339.30.6367.70.5280.2160.28Lu120.3543.00.7365.80.4073.3100.44Lu130.4036.30.3264.90.3677.3150.28Lu140.1154.00.4881.00.6788.280.45Lu160.3940.70.3176.6-84.790.32Lu170.1133.30.5959.90.5667.1120.55Lu180.1022.00.4768.60.23106.5220.21Mean0.1534.70.55\*63.10.42\*78.6170.34\*Standard deviation0.1413.30.1715.40.1516.490.17\**p* \< 0.008^a^Outlier

Dosimetry {#Sec13}
---------

The absorbed doses to the blood in the individual patients were calculated according to Eq. [1](#Equ1){ref-type=""}. The mean absorbed dose was 34 ± 13 mGy at 4 h, 63 ± 15 mGy at 24 h and 79 ± 16 mGy at 48 h after administration (Table [2](#Tab2){ref-type="table"}). The relative contribution of the penetrating radiation to the absorbed dose 48 h after treatment was less than 34 % in all patients. In the first few hours after treatment the contribution was below 10 % (data not shown). Due to the lack of data at time points \> 2 days, and the associated uncertainty in extrapolating the data to time infinity, the total absorbed dose was not calculated. The absorbed dose to the blood increased steeply in the first few hours after therapy (Fig. [2](#Fig2){ref-type="fig"}). In most patients, 50 % of the absorbed dose to the blood at 48 h was reached within the first 5 h. In accordance with this observation, the dose-rate decreased until it was less than 0.5 mGy/h after 48 h. For comparison, Fig. [3](#Fig3){ref-type="fig"} shows the average number of RIF per cell for this example patient (Lu3) as a function of the absorbed dose to the blood.Fig. 2Absorbed dose to the blood (**a**) and corresponding dose rate (**b**) in a selected patient (Lu3)Fig. 3Average RIF per cell as a function of the absorbed dose to the blood in patient Lu3. The blood sampling times were: 0, 0.6, 1.1, 1.7, 2.3, 3.6, 24.1 and 44.7 h

In vivo calibration of the DNA damage focus assay {#Sec14}
-------------------------------------------------

The average numbers of RIF per cell as a function of the absorbed dose in each patient for the first 5 h after treatment are shown in Fig. [4](#Fig4){ref-type="fig"}. The first datasets up to 5 h after administration of the radiopharmaceutical were pooled. A linear fit to our ^177^Lu patient data (in vivo calibration) resulted in: *y* = 0.0321 + 0.0127·*x*, where *y* denotes the number of RIF per cell and *x* the absorbed dose to the blood in milligray (*R*^2^ = 0.72). The standard error of the *y*-axis intercept was ± 0.0152 RIF per cell and the standard error of the slope was ± 0.0009 RIF per cell · mGy^−1^. The *y*-axis intercept value in this case takes the standard deviation of the background (maximum value ± 0.09 RIF per cell) value into account. Therefore, we did not force it to zero, although, no RIF per cell would be expected at 0 mGy. For absorbed doses above 10 mGy the influence of the *y*-axis intercept on the number of RIF per cell was less than 20 %. The resulting in vivo calibration curve for our ^177^Lu patient data including the 95 % confidence interval is also shown in Fig. [4](#Fig4){ref-type="fig"}. In a previous study we obtained an in vitro calibration curve for ^131^I and ^177^Lu from blood samples of volunteers \[[@CR27]\]. For comparison this in vitro calibration curve is shown in Fig. [4](#Fig4){ref-type="fig"}. The relative deviation of the slopes between the in vitro calibration curve and the in vivo data is 14 %.Fig. 4Average number of RIF per cell as a function of the absorbed dose to the blood (over the first 5 h after ^177^Lu administration). The *black line* is the linear fit to our ^177^Lu patient data (in vivo calibration curve) including the 95 % confidence interval (CI), and the *red line* is the in vitro calibration curve taken from Eberlein et al. \[[@CR27]\] including the 95 % CI

Modelling {#Sec15}
---------

Individual fits of the patient data were performed according to Eq. [2](#Equ2){ref-type=""} using the datasets for the biokinetics of blood (*λ*~*bl*\ 1,2~, *A*~*bl*\ 1,2~) and the total body (*λ*~*tb*\ 1,2~ and *A*~*tb*1,2~) provided in Table [S1](#MOESM1){ref-type="media"} as well as the values of the in vitro calibration \[[@CR27]\] (*a* and *b*). Variable parameters to be fitted were *m* (adjustable parameter to account for the variability in the patient dosimetry with respect to the in vitro calibration) and the repair rate *λ* (Table [S1](#MOESM1){ref-type="media"}). For this study we chose *k* = 1 in Eq. [2](#Equ2){ref-type=""}, thus describing the repair in terms of a monoexponential function only. The reason was that we obtained only two blood samples per patient at 24 h and 48 h after administration, which was not sufficient for an adequate approximation of a biexponential function. Because of the lack of late data points only a monoexponential fit was possible; therefore, we could not provide a second repair rate *ν*.

In general, the data followed the in vitro calibration curve for the first 5 h after treatment. The mean value of the fitted parameter *m* which accounts for the variability in patient dosimetry with respect to the in vitro calibration was 1.28 ± 0.66 (minimum 0.55, maximum 2.84). The mean decay rate (*λ*) in all patients was 0.0379 ± 0.0187 h^−1^ (minimum 0.014 h^−1^, maximum 0.084 h^−1^) corresponding to 18.3 h effective decay time. The maximum of this fitted curve including the average parameters of all patients was at 7.2 h after administration of ^177^Lu. After 75.5 h the average number of RIF per cell dropped below the maximum standard deviation of the baseline value of 0 ± 0.09 RIF per cell (Fig. [5](#Fig5){ref-type="fig"}). The standard deviation of the background foci included the counting error. Therefore, each data point was considered with appropriate error propagation, even the baseline value of RIF per cell at 0 mGy.Fig. 5Average number of RIF per cell as a function of time after ^177^Lu administration, including the modelled decay function using the mean values of all foci--decay fits according to Eq. [2](#Equ2){ref-type=""}. Parameters are the mean values presented in Table [S1](#MOESM1){ref-type="media"}

Discussion {#Sec16}
==========

This study provides a first clear correlation between the average number of RIF per cell and the absorbed dose to the blood after PRRT up to 5 h after administration of the β-emitter ^177^Lu. Absorbed doses to the blood of nearly all patients were less than 100 mGy 48 h after treatment. Concomitant generation of a significantly elevated number of radiation-induced DSB foci was noted up to 48 h after therapy (end of our follow-up).

Recently, Denoyer et al. \[[@CR31]\] analysed the kinetics of γ-H2AX foci formation in peripheral blood lymphocytes of 11 patients undergoing PRRT. The number of γ-H2AX foci in 50 -- 100 cells per sample was determined before and up to 72 h after treatment using a dedicated computational algorithm (TGIR foci-counting software) \[[@CR42]\]. Denoyer et al. observed a variable response among patients, but, unlike our findings, detected no clear relationship between the absorbed dose to the blood and the number of γ-H2AX foci. The correlations between γH2AX foci yield and the absorbed doses presented by the authors are poor or, in the case of bone marrow, lead to a negative number of γ-H2Ax foci for bone marrow doses \<100 mGy, a fact which is neither explained nor discussed \[[@CR42]\].

While there are many studies showing elevated foci levels after exposure to ionizing radiation \[[@CR33], [@CR40], [@CR43]--[@CR48]\], only a limited number of studies have shown the effects of the therapeutic or diagnostic use of radionuclides \[[@CR29]--[@CR31], [@CR35]\]. For internal irradiation in molecular radiotherapy the time-course of the induction and the number of RIF are different from those following external irradiation, since after radionuclide administration cells are irradiated not only for seconds or minutes, but are continuously irradiated over a longer period of time with a permanently changing dose rate \[[@CR29]\].

Blood-based dosimetry in PRRT using ^177^Lu shows several differences from blood-based dosimetry of radioiodine as, for example, described by Hänscheid et al. \[[@CR49]\]. The absorbed dose to the blood from the penetrating radiation of ^177^Lu is almost an order magnitude lower than that from ^131^I. Therefore, the contribution of penetrating radiation to the absorbed dose to the blood is in most patients less than 20 % at 48 h after administration of ^177^Lu, and even less in the first few hours after administration (data not shown). However, it is unknown how the absorbed dose to the blood from penetrating radiation changes due to uptake in the liver, spleen, tumour and metastases. The mean observed absorbed dose to the blood after 48 h in the ^177^Lu-treated patients in this study was lower than the values reported by Lassmann et al. \[[@CR29]\] for ^131^I-treated thyroid carcinoma patients. In agreement with Sandström et al. \[[@CR50]\], this can mainly be attributed to the fact that the activity in the blood has a shorter half-life in the first hours after ^177^Lu administration than after ^131^I administration. For clinical reasons, the blood sampling times, particularly for the first samples, were variable and therefore, the first phase of the blood time--activity curve might not have been a satisfying representation in all patients, a fact which may have affected the correlation with the RIF induced in the first few hours after administration of the radiopharmaceutical.

Overall, the absorbed doses to the blood were low in all patients receiving ^177^Lu therapy, indicating that the likelihood of haematological toxicity is rather low for this treatment, in agreement with the findings of Sandström et al. in 200 patients \[[@CR50]\]. In a previous radioiodine DTC study we also observed the decay in the average number of RIF per cell after radioiodine therapy of DTC \[[@CR29]\], with the highest number of RIF per cell being observed 2 h after therapy; however, no blood samples were available for the next few hours, while the decrease of in the number of RIF per cell \[[@CR29]\] at later time-points mirrored the findings of the present study. Doai et al. \[[@CR30]\] observed no temporal dependency of γ-H2AX foci and the absorbed dose to the blood, probably because their first blood collection was at 96 h after radioiodine administration, a time period that is, according to the current results and our experience, too late to reveal a direct dose--response relationship. May et al. \[[@CR35]\] investigated the induction of γ-H2AX foci by a PET tracer (^18^F-FDG) used in nuclear medicine diagnostics. However, in that study the FDG PET (β-exposure) was followed by exposure to X-rays from CT. Thus, the exposure to X-rays has likely obscured any RIF induced by the radiopharmaceutical.

The observed numbers of RIF per cell for the first hours after treatment obtained in this work are in good agreement with the in vitro calibration curve \[[@CR27]\] developed in our laboratory. The slight differences in slope in relation to the in vitro calibration curve can be explained by the results of two recent studies by Hänscheid et al. \[[@CR51], [@CR52]\] in which the authors investigated the absorbed doses to the blood from compounds that do not bind to the blood. According to these results \[[@CR51]\] the gamma component is underestimated for ^177^Lu by a factor of about 2 as compared to the model we assumed. In addition, when a realistic distribution of vessel sizes is taken into account this results in a beta absorbed dose that is lower than the maximum energy deposited by beta particles \[[@CR52]\]. A specific model for the case of PRRT describing the absorbed dose to the blood is so far not available.

We are aware that the numbers of RIF per cell strongly depend on the background values of the patients. As can be seen in Table [2](#Tab2){ref-type="table"}, these values underlie strong intrinsic variations, possibly related to age, lifestyle, nutrition, genetics background and stress. Cell fixation as well as staining artefacts can also play a role in variability \[[@CR48]\]; however, we controlled for this by including internal 0 Gy and 1 Gy controls in all staining reactions. Only staining reactions in which control values were similar were evaluated. Other studies have also shown a high variability in background values \[[@CR29], [@CR31], [@CR46], [@CR53], [@CR54]\]. Overall, these findings show that the DNA damage focus assay may be used as an in vivo dosimeter in the first hours after incorporation of beta-emitting radioisotopes.

The disappearance of RIF as a function of time has been quantitatively investigated by Horn et al. \[[@CR40]\] and by Mariotti et al. \[[@CR41]\], with the former describing the disappearance using a biexponential decay function with a short decay rate of 0.350 h^−1^ (77 %) and a longer-lived component of 0.018 h^−1^ (23 %). Mariotti et al. also described, for a single acute absorbed dose of 1 Gy, biexponential decay with a short component (relative contribution 91 %, decay constant 0.23 h^−1^) and a second phase that showed almost no decay (relative contribution 9 %, 3.32 × 10^−12^ h^−1^). In the current study, for logistic reasons, we were only able to include two blood samples per patient obtained \>5 h after administration of ^177^Lu. Hence, we decided to describe the decay using a monoexponential function only. Our RIF per cell decay rates lie, with one exception (patient Lu14: 0.014 h^−1^), within the range of values reported by Horn et al. \[[@CR40]\]. The value for patient Lu14 could potentially be interpreted as showing a lower repair rate of DNA damage than in the other patients; however, this finding could also be explained by the variability in the individual patient dosimetry data. In patients with a very low repair rate (patients Lu14 and Lu16) or a very high repair rate (patients Lu6 and Lu18), no obvious link between these findings the condition of the patients, and the pretreatments or stage of disease could be found.

Further studies with more patients and different tracer kinetics in the blood are needed to better identify patients with deviating repair rates.

Conclusion {#Sec17}
----------

This study shows the effect of ionizing radiation on blood lymphocytes after systemic administration of a radiopharmaceutical in the course of PRRT as a function of the absorbed dose to the blood. For the first time a clear correlation between the average number of RIF per cell and the absorbed dose to the blood up to 5 h after ^177^Lu administration has been established. In the first hours after ^177^Lu administration, the average number of RIF per cell closely followed our in vitro calibration curve, thereby enabling the use of the DNA focus damage assay as an in vivo dosimeter. At 24 h and 48 h after ^177^Lu administration the mean number of RIF decreased, in accordance with the progression of DNA repair and declining dose rates.
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